Q1 2025 Management View Veru highlighted its transformation into a late clinical-stage biopharmaceutical company focusing on cardiometabolic and inflammatory diseases, with major developments in ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

In a Phase 2b trial, older patients taking Novo Nordisk’s Wegovy and Veru’s experimental drug, called enobosarm, lost on average 1.2% of lean mass after 16 weeks, compared with a 4.1% loss in ...

Enobosarm + semaglutide reduced lean mass loss by 71% and increased fat mass loss by 27% vs. Wegovy alone. Phase 2b extension trial to assess weight loss maintenance is ongoing, with results ...

The Phase 2b QUALITY clinical study was placebo-controlled dose-finding study to evaluate the safety and efficacy of enobosarm 3mg, and enobosarm 6mg, vs. placebo in 168 older patients ...

The Miami-based company has been testing two doses of its oral selective androgen receptor modulator enobosarm in a phase 2b trial of 168 patients aged over 60 years who are overweight or with ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

Veru declined over 40% to Patients on Veru's oral drug, enobosarm, and Wegovy lost 71% less lean muscle on average than those who received placebo and Wegovy over 16 weeks. Those who received the ...

CEO Mitchell Steiner highlighted enobosarm and sabizabulin as the company's key clinical-stage drugs. Enobosarm is being developed to improve GLP-1 receptor agonist therapies by preserving lean ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as ...